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Abstract
Grafts generated by cultivation of progenitor cells from
the stromal vascular fraction of human adipose tissue have
been proven to have osteogenic and vasculogenic properties
in vivo. However, in vitro manufacture of such implants is
challenged by complex, impractical and expensive
processes, and requires implantation in a separate surgery.
This study investigates the feasibility of an intraoperative
approach to engineer cell-based bone grafts with tissue
harvest, cell isolation, cell seeding onto a scaffold and
subsequent implantation within a few hours. Freshly
isolated adipose tissue cells from a total of 11 donors,
containing variable fractions of mesenchymal and
endothelial progenitors, were embedded at different
densities in a fibrin hydrogel, which was wrapped around
bone substitute materials based on beta-tricalcium
phosphate (ChronOS®), hydroxyapatite (Engipore®), or
acellular xenograft (Bio-Oss®). The resulting constructs,
generated within 3 hours from biopsy harvest, were
immediately implanted ectopically in nude mice and
analysed after eight weeks. All explants contained blood
vessels formed by human endothelial cells, functionally
connected to the recipient’s vasculature. Human origin cells
were also found within osteoid structures, positively
immunostained for bone sialoprotein and osteocalcin.
However, even with the highest loaded cell densities, no
frank bone tissue was detected, independently of the
material used. These results provide a proof-of-principle
that an intraoperative engineering of autologous cell-based
vasculogenic bone substitutes is feasible, but highlight that
– in the absence of in vitro commitment – additional cues
(e.g., low dose of osteogenic factors or orthotopic
environmental conditions) are likely needed to support
complete osteoblastic cell differentiation and bone tissue
generation.
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Introduction
The engineering of osteogenic bone substitute grafts based
on scaffolds loaded with osteoprogenitors offers an
attractive opportunity for the replacement of post-
traumatic bone loss, treatment of delayed or non healing
fractures or fusion of degenerated joints (Cancedda et al.,
2003). The concept has the potential to overcome the main
limits associated with autologous bone, currently the
golden standard bone graft, namely donor site morbidity
(Ahlmann et al., 2002; Arrington et al., 1996; Niedhart et
al., 2003; Sasso et al., 2005; Silber et al., 2003) and
reduced availability (Boden, 2000; Younger and
Chapman, 1989). However, in addition to the reported
challenges in reproducibility of performance (Meijer et
al., 2007), routine clinical implementation of autologous
cell-based engineered bone grafts is challenged by the
complexity, impracticality and high costs of the
manufacturing process (Evans et al., 2007). This is
predominantly due to the need for two surgical procedures
(respectively for cell harvest and graft implantation) and
extensive ex vivo cell manipulation and culture under
Good Manufacturing Production regulations/facilities.
Engineering of autologous osteogenic grafts would
have the potential to become more simple, practical and
economical if the manufacturing process was reduced to
the timeline of a single surgical procedure. An
intraoperative approach was proposed starting from bone
marrow-derived mesenchymal stromal cells, either
immunoselected for CD105 (Aslan et al., 2006) or in
combination with a gene therapy approach (Evans et al.,
2007). Considering that clonogenic osteoprogenitor cells
(colony forming unit-fibroblasts, CFU-f) are present in
human fresh bone marrow biopsies at low frequencies
(about 0.01% of the total mononucleated cells), further
decreasing with donor age (Muschler et al., 2001), their
availability could become a limiting factor, especially for
the reconstruction of large bone defects. In this context,
it was proposed that the stromal vascular fraction (SVF)
of adipose tissue could represent a more suitable cell
source for a one-step surgical procedure (Helder et al.,
2007). Indeed, clonogenic mesenchymal cells in SVF from
human lipoaspirates are about 5% of the total cell
population, corresponding – when normalized to the
biopsy volume - to around 500-fold larger numbers than
in human bone marrow aspirates (Fraser et al., 2006;
Scherberich et al., 2007). Moreover, SVF cells are known
to include a fraction of endothelial lineage cells (Planat-
Benard et al., 2004), which could play an important role
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in the crucial process of graft vascularization (Scherberich
et al., 2007). However, despite promising perspectives, to
the best of our knowledge it has not yet been convincingly
demonstrated that freshly harvested SVF cells can
effectively induce bone tissue or enhance its repair. In fact,
SVF cells did not generate frank bone tissue when
implanted in a goat orthotopic intervertebral model (Helder
et al., 2007), and were not capable to induce bone
formation when grafted subcutaneously in a rabbit model
(Follmar et al., 2007).
We recently demonstrated that human SVF cells,
seeded and cultured for 5 days within 3D porous ceramic
scaffolds using a perfusion-based bioreactor system,
generated grafts capable to induce ectopic bone formation
in nude mice, as well as a network of blood vessels
functionally connected to the host vasculature (Scherberich
et al., 2007; Müller et al., 2009). Supported by those
promising findings, in the present study we aimed at
developing osteogenic and vasculogenic grafts using
human SVF cells in a setting compatible with an
intraoperative clinical implementation. In particular,
freshly harvested SVF cells were associated to different
types of scaffolds including a mineral/ceramic component,
and implanted ectopically in nude mice without pre-culture.
Based on the need to rapidly generate the constructs, a




Subcutaneous adipose tissue was obtained in the form of
lipoaspirates (n=3) or excised fat samples (n=8) from 11
healthy donors (10 female, 1 male; mean age 32±15years)
undergoing abdominal wall plasty (n=5), breast reduction
(n=3) or routine liposuction of the thigh and the abdominal
wall (n=2 and n=1 respectively). All donors gave their
informed consent and the study protocol was approved by
the local ethical committee. Excised fat samples were
minced into pieces of 2-4 mm in diameter. Both minced
fat and lipoaspirates were digested with 0.15% (W/V) type
II collagenase for one hour at 37°C under orbital shaking.
The suspension was then centrifuged at 400 g for 4 minutes.
The resulting pellet was washed in phosphate buffered
solution (PBS, Gibco, Invitrogen, Carlsbad, CA, USA),
resuspended in α-Modified Eagle’s Medium (α-MEM,
Gibco) containing 10% of foetal bovine serum (FBS,
Gibco) and passed through a 100μm strainer. Red blood
cells were lyzed by incubation for 5 minutes with a buffer
containing 0.15 mol/l ammonium chloride, 1.0 mmol/l
potassium bicarbonate and 0.1 mmol/l Na-EDTA. After
centrifugation and washing in PBS, the SVF cells were
suspended in α-MEM supplemented with 10% FBS and
counted by using a Neubauer chamber.
Cell characterisation
The frequency of clonogenic cells among isolated SVF
cells, also referred to as fibroblastic colony forming units
(CFU-f), was determined by plating 500 freshly isolated
SVF cells per 56cm2 Petri dish in duplicates. The cells
were then cultured for 14 days in 10% FBS containing α-
MEM supplemented with 5ng/ml FGF-2 (thereafter
referred to as complete medium). The resulting colonies
were stained with crystal violet and counted.
The phenotype of freshly isolated SVF cells was
determined by cytofluorimetric analysis. Cells were
incubated for 30 minutes with antibodies against the
mesenchymal markers CD105 (conjugated with FITC,
Serotec, Oxford, U.K.) and CD90 (FITC-conjugated, BD
Bioscience, Franklin Lakes, NJ, USA), and against the
endothelial markers CD31 and CD34 (PE- and APC-
conjugated respectively, both from BD Bioscience). Cells
were washed, resuspended in PBS and analyzed by using
a FACSCalibur flow cytometer (BD Bioscience).
Fabrication and implantation of SVF cells-fibrin-
scaffold constructs
To obtain a fibrin mesh supporting cell proliferation and
migration, fibrinogen and thrombin components from
Tisseel VH S/D (Baxter BioScience, Vienna, Austria) were
diluted and mixed as described by Bensaid et al. (Bensaid
et al., 2003). The fibrinogen component (containing 75-
115 mg/ml fibrinogen, + 3000 KIE/ml aprotinin) and the
thrombin component (containing 400 -600 IU/l thrombin
+ 40mmol/l calcium chloride) were diluted respectively
3- and 4-fold using specific buffers provided by Baxter.
These buffers were formulated to only dilute the protein
components, while leaving the excipient and ionic
environment of the components constant. Then, various
amounts of freshly isolated SVF cells were loaded onto
porous tri-calcium phosphate (Chronos®, Synthes, West
Chester, PA, USA) or hydroxyapatite (Engipore®, Fin-
Ceramica Faenza, Italy) cylinders (4mm height, 8mm
diameter) or blocks of acellular xenografts (Bio-Oss®
collagen, Geistlich Pharma AG, Wolhusen, Switzerland,
4mm x 5mm x 6mm beams) using fibrin gel as a cell carrier,
as shown in Fig. 1. Briefly, freshly isolated adipose tissue
derived cells were suspended in 150 μl of diluted
fibrinogen component and mixed with an equal volume
of the diluted thrombin component in a well. The resulting
fibrin-cell matrix (Fig. 1A) was then wrapped around the
above-mentioned scaffolds (Fig. 1B). Loaded scaffolds and
the fabrication well were stained by Methyltetrazolium
(MTT) to qualitatively assess efficiency and uniformity
of cell loading after the wrapping process (Fig. 1 C,D).
Upon fabrication, all constructs were maintained in a
humidified incubator (37°C/5% CO2) for 15 minutes, cut
in two halves and implanted in the subcutaneous tissue of
different nude athymic mice (CD1 nu/nu, Charles River,
Sulzfeld, Germany). The total construct preparation time,
starting from the harvest of the tissue biopsy to the
implantation, was typically within 3 hours. Eight weeks
after implantation, the mice were sacrificed by inhalation
of CO2. The constructs were harvested, fixed in a 4%
formalin buffer overnight and processed as described
below.
Assessment of in vivo bone formation
Decalcification of the constructs was performed by
incubation with Osteodec® (Bio Optica, Milan, Italy) at
37° for 3-4 hours on an orbital shaker. Decalcified
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constructs were paraffin-embedded and sectioned (7 μm
thick). Sections were stained with Haematoxylin & Eosin
and Masson’s trichrome and observed by light and
fluorescence microscopy.
For further analysis of bone formation, immunostaining
with polyclonal rabbit antibodies against human bone
sialoprotein (Immunodiagnostik AG, Bensheim, Germany)
and human osteocalcin (Chemicon/Millipore, Billerica,
MA, USA) was performed and visualised by ABC alkaline
phosphatase complex kit (Dako, Glostrup, Denmark),
followed by counterstaining with haematoxylin.
To distinguish between human and recipient (mouse)
cells, we performed in situ hybridization for ALU
sequences, specific of the human genome, and
immunostaining for HLA-ABC. For in situ hybridization,
sections were incubated with pepsin at 37° C for 5 minutes
followed by irrigation with 100% ethanol for 10 seconds
and distilled water for 30 seconds. Hybridization with a
biotin conjugated DNA probe (ZytoVision, Bremerhaven,
Germany) specific for ALU sequences was carried out
according to manufacturer’s instructions. The biotin
conjugated DNA probe was detected by addition of
alkaline phosphatase complex (Dako) and subsequent
staining with fast red. Immunohistofluorescence staining
for HLA-ABC was carried out on sections with a
monoclonal HLA-ABC-biotin conjugated antibody
(Cedarlane Labs, Burlington, Ont., Canada) and
subsequent incubation with avidin-FITC (BD Bioscience).
Assessment of in vivo blood vessel formation
To demonstrate the presence of donor-derived functional
blood vessels, we performed immunohistochemistry using
Fig. 1: Loading of SVF cells on scaffolds by embedding cells in a fibrin matrix and subsequent wrapping around the
scaffolds (process illustrated for the loading of an Engipore® scaffold). Freshly isolated adipose tissue derived cells
were suspended in 150 μl of the fibrinogen component and transferred into a well. The cell suspension was then
mixed with an equal volume of thrombin. The resulting fibrin-cell matrix (A) was then wrapped around the scaffolds
(B). MTT staining showed a rather scattered distribution of SVF cells on the surface of the scaffold (C) but no cells
remaining in wells (D) following the loading process.
Abbreviations: SVF: stromal vascular fraction, MTT: Methyl tetrazolium
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a biotin-conjugated antibody directed specifically against
the human isoform of CD34 (Chemicon/Millipore). Prior
to incubation with the antibody, de-paraffinized sections
were immersed for 30 minutes in a target retrieval solution
(Dako) at a temperature of 95°C. The binding of the anti-
human CD34 was visualised by ABC alkaline phosphatase
complex kit (Dako).
Results and Discussion
Cell isolation and characterization
After the digestion of adipose tissue and subsequent
centrifugation, the resulting SVF yielded 1.7x105 ± 1.2x105
nucleated cells, of which 7.0 % ± 5.7% were clonogenic,
colony-forming cells (typically referred to as CFU-f). The
high variation of nucleated cells frequency per volume of
harvested adipose tissue was due to substantially lower
yields obtained from one excised breast fat sample and
from one lipoaspirate (4.5x103 and 4.7x104 nucleated cells/
ml of harvested tissue, respectively). Both samples were
highly fibrous, possibly explaining the reduced efficiency
in the cell isolation process. Since the clonogenic cell
frequency in these two samples was in a typical range, the
constructs generated from these donors were included for
further analysis. Overall, the frequency of CFU-f did not
substantially differ between samples used to load
Engipore® and ChronOS® cylinders (7.3±5.3% and
8.4±7.2%, respectively), but happened to be lower in
samples used to load Bio-Oss® blocks (3.3±1.2%).
Engipore® and ChronOS® cylinders were seeded with
8.3x106-39.2x106 freshly isolated SVF cells/cm3,
corresponding to 1.2x105-3.6x106 CFU-f/cm3 in a total of
8 and 12 experiments, respectively. Bio-Oss® blocks were
loaded with 8.3x106-25.0x106 nucleated cells/cm3,
corresponding to 1.7x105-1.1x106 CFU-f/cm3, in a total of
7 experiments. MTT staining of cell-scaffold constructs
and of the fabrication well following construct generation
indicated a complete but rather scattered cell seeding on
the scaffold surface (Fig. 1C,D), which could account for
higher cell densities in localized areas. Efforts should be
made in the future to reach a higher homogeneity of the
cell seeding, for instance by mixing the polymerizing cell-
containing fibrin gel with the granulate ceramic scaffolds.
Cytofluorimetric analysis of SVF cells documented the
presence of mesenchymal and endothelial lineage cells
(Fig. 2). Their frequency was variable among different
donors, as previously reported (Scherberich et al., 2007),
but comparable between the samples allocated to the
different scaffold groups.
Assessment of in vivo bone formation by SVF cells
After 8 weeks in vivo, in 11 out of 27 constructs implanted,
corresponding to all samples seeded with more than 2.106
CFU-f/cm3 (Engipore or ChronOs), a very dense
collagenous matrix was observed by standard H&E and
Masson Trichrome staining (Fig. 3C-F). This matrix
resembled osteoid tissue, which is the organic, collagen-
rich portion of the bone matrix that forms prior to the
maturation of bone tissue and its mineralization, and which
is stained in green by Masson Trichrome. However, no
frank bone, with its typical histological morphology, was
observed. In contrast, when less than 2.106 CFU-f/cm3 were
seeded, no such dense matrix was observed but a more
fibrotic tissue was formed (Fig. 3A,B and G). It was
retrospectively observed that since the Bio-Oss were
seeded with cells from patients with low CFU-f
frequencies, this resulted in the fact that only the
experimental condition with less than 2 million CFU-f/
cm3 was assessed with this material. This is likely to
explain why no dense matrix was formed in Bio-Oss (Fig.
3G). When cell-free materials were implanted in vivo
(Chronos® shown in Fig. 3H, other materials not shown),
pores were filled only with adipose tissue and large calibre
blood vessels arising from ingrowth of mouse tissue. The
osteoid-like matrix observed with more than 2.106 CFU-f/
cm3 was strongly positive for typical osteoblastic markers
such as bone sialoprotein and osteocalcin (Fig. 4A,B,C).
Immunostaining for HLA-ABC (Fig. 4D,E) and in situ
hybridization for ALU sequences (Fig. 4H) demonstrated
Fig. 2: Expression of mesenchymal (CD105 and CD90) as well as endothelial (CD34 and CD31) markers in the
stromal vascular fraction (SVF) of all donors (first column) and in the SVF of donors allocated to the different
scaffold types.
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the human origin of cells within this dense matrix.
Interestingly, SVF cells, initially present only at the
periphery of the scaffolds, invaded even the most central
regions of the constructs in vivo. This process could have
been facilitated by the specific fibrinogen and thrombin
concentrations used, previously reported to support cell
migration (Bensaid et al., 2003).
The absence of bone tissue formation observed in this
study, at least in the time frame of 8 weeks, needs to be
discussed in the context of the in vivo model used. In fact,
we decided to test the intrinsic osteogenic properties of
the grafts, and therefore implanted them in an ectopic
environment, which does not include the biological and
biomechanical cues present in proximity to bone tissue.
Subcutaneous implantation is a stringent test of
osteogenicity also for bone marrow-derived mesenchymal
stromal cells, and was demonstrated to require (i) a
mineralized surface for priming osteoblastic differentiation
(Ohgushi et al., 1989; Ohgushi and Okumura, 1990;
Eyckmans et al., 2009), and (ii) a critical density of
implanted clonogenic cells (Braccini et al., 2005; Holy et
al., 2000). In our study, these conditions were satisfied,
since we loaded cells onto different types of calcium
phosphate-based scaffolds, using a density of clonogenic
cells largely exceeding the range (2.5x105–3x105
clonogenic cells/cm3) previously reported to support
ectopic osteogenesis by human bone marrow-derived
CFU-f (Braccini et al., 2005). Thus, the absence of frank
bone formation suggests an intrinsically reduced
osteogenic commitment of adipose tissue- vs. bone
marrow-derived CFU-f. On the other hand, following short
term cultivation (5 days) in a perfusion-based bioreactor,
SVF cells from human adipose tissue were demonstrated
to generate ectopic bone tissue (Scherberich et al., 2007).
Although it is not clear which culture parameters were
crucial in the process (e.g., flow induced shear, osteogenic
medium supplements, 3D cell organization), the result
confirms that the cells indeed have an osteogenic capacity,
if appropriately triggered.  In order to exploit such capacity
within an intraoperative setting, future studies should
investigate the effect of a short exposure of SVF cells to
osteogenic growth factors (Helder et al., 2007; Aslan et
Fig. 3: Light microscopy pictures
of hematoxylin and eosin
(A,B,C,D,G) and Masson
trichrome (E,F)-stained sections of
constructs ectopically implanted
for 8 weeks in nude mice and
generated by wrapping fibrin
embedded SVF cells around
ChronOS® (B,D,F) or Engipore®
(A,C,E) cylinders, and blocks of
Bio-Oss® (G). A very dense matrix
(dm) was observed in all scaffold
types when the initial density of
clonogenic cells inside the scaffold
was higher than 2.106 clonogenic
cells/cm3,(C-F), whereas mostly
fibrotic tissue was formed with
densities below 2.106 clonogenic
cells/cm3 (A,B). This dense matrix
showed closer similarity to osteoid
tissue (ot) in scaffolds initially
loaded with more than 3.106
clonogenic cells/cm3 (E,F), as
shown by microscopy images of
representative fields. (H)
Represents the hematoxylin and
eosin-stained section of a cell free
ChronOs® scaffold ectopically
implanted for 8 weeks in nude mice
showing ingrowths of mouse
tissue, especially adipose tissue
(adi) and blood vessels (bv). Scale
bars = 100 μm (A,B,C,E,F,H) or
50 μm (D). The number of
independent donors tested for each
condition is reported in the upper
left corner of each image.
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Fig. 4: Immohistochemistry (A,B,C,F,G), immunoflurorescence (D,E) and in situ hybridization (H) of explanted
constructs.  The dense matrix (dm) was positively stained for bone sialoprotein (B, red staining) and osteocalcin (C,
pink staining shown by arrowhead). Isotype control antibodies showed no relevant unspecific binding (A). Explanted
constructs included human donor-derived cells, as demonstrated by immunofluorescent staining for HLA-ABC (E,
light green cells shown by green arrows) and in situ hybridization with probes for human-specific ALU sequences
(H, blue nuclei shown by blue arrowheads). Isotype control for HLA-ABC showed no background staining (D). As
demonstrated by staining for the human isoform of CD34 (G, isotype control shown in F), a fraction of SVF cells
supported the formation of functional blood vessels in vivo (red structures shown by arrowheads). Scaffolds used in
the results shown were Engipore® (C-E, H) or ChronOs® (A,B,F,G). Bars: 200 μm.
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al., 2006), supplemented into the culture medium or bound
to the carrier material (Park et al., 2006), possibly at lower
doses than those typically employed for cell-free
osteoinductive grafts. Alternatively, scaffolds with more
instructive chemical and structural characteristics
(Ripamonti et al., 2008) should be coupled with freshly
harvested SVF cells to prime their osteoblastic
differentiation. Ultimately, however, tests of osteogenicity
will have to be performed in an orthotopic, loaded in vivo
model, still allowing the use of human-derived cells but
more closely corresponding to a possible clinical scenario
(e.g., using nude rats and the RatFix™ system, AO
Foundation, Davos, Switzerland).
Assessment of human blood vessel formation by SVF
cells
As shown in Fig. 4F,G, some blood vessels inside the
constructs were lined with human (and not mouse)
endothelial cells, as demonstrated by immunostaining for
the human isoform of CD34. These blood vessels contained
erythrocytes, indicating that they were functionally
connected to the vasculature of the host. The human cell-
derived vascularization of the implant, so far not observed
in previous constructs generated intraoperatively (Helder
et al., 2007), appeared to be independent of the scaffold
type used and of the number of cells initially loaded onto
the scaffold. The reproducibility of donor-derived
vascularization in the constructs suggests a strong vascular
commitment of adipose tissue-derived endothelial
precursors and underlines the previously reported capacity
of SVF cells to support vascularization (Scherberich et
al., 2007, Thangarajah et al., 2009). It remains to be
demonstrated whether the presence of functional
endothelial lineage cells will effectively accelerate or
improve vascularization of the graft, which may become
crucial in the process of scaling-up to critically sized
dimensions.
Conclusion
In conclusion, this study describes the feasibility of a
clinically-compliant method for the intraoperative
generation of autologous bone substitute constructs, based
on lipoaspirate cells. The preparation of the grafts was
achieved within 3 hours from the biopsy harvest, and the
times could be further reduced by appropriate selection of
the enzyme combination and concentration, as well as by
the availability of clinical grade devices for cell isolation
from the adipose tissue (e.g., Celution® by Cytori
Therapeutics, U.S.A or Sepax® by Biosafe, Switzerland).
Overall, no major qualitative differences between the
scaffolds were observed for parameters such as formation
of dense tissue or of blood vessels by implanted cells. These
cells had a reproducible vasculogenic capacity, whereas
effective de novo bone formation in an ectopic mouse
model could not be demonstrated. The result indicates that
cell density or specific properties of the mineralized
substrates used are not sufficient per se to instruct SVF
cells to develop along the osteogenic lineage in an inert,
ectopic environment. Future studies will thus have to test
if short time stimulation of adipose tissue-derived cells
with osteoinductive factors, or the use of an orthotopic
model in a loaded skeletal area will possibly turn the
premature osteoid matrix observed in the present study
into mature bone, and thus open the way to a clinical testing
of this approach.
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Discussion with Reviewers
Reviewer I: Should the experiments be reprogrammed
using sorted cell populations instead of a total lipo-
aspirate? It could still be done “intraoperative”.
Authors: The concept of sorted cell populations is indeed
attractive, and – considering the inter-donor variability in
the fractions of cells with different phenotypes – this
approach would be crucial to standardize the ‘dose’ of
appropriate cells that need to be delivered per volume of
tissue to be regenerated. However, obviously that requires
the availability of markers identifying the effectively
osteogenic/vasculogenic subpopulations and the
demonstration that the other ‘accessory’ cells do not play
a crucial regulatory role.
Reviewer I: How about using marrow stroma as a control?
Authors: The use of bone marrow stromal cells is currently
being investigated by other groups in a ‘one-step’
intraoperative perspective. We do not see this independent
approach as a possible ‘control’ of our experimental
groups, but sure worth being further pursued. While bone
marrow derived cells have a preferential ‘commitment’
towards the osteogenic lineage, the challenge in using
freshly harvested bone marrow is the extremely low
number of initially available osteoprogenitor cells, which
also limits the possibilities to operate some form of in-line
quality control of the available material. Specifically, the
number of colony forming unit-fibroblasts, CFU-f, per ml
of human fresh bone marrow biopsies is about 100-fold
lower than in adipose tissue (Scherberich et al., 2007, text
reference), further decreasing with donor age (Muschler
et al., 2001, text reference). Ultimately, the question asked
leads thus to the critical issue that an appropriate cell source
should provide a suitable balance between the commitment
and the number of progenitor cells available. On top of
these considerations, it should also be underlined that, in
an effort to generate osteogenic and vasculogenic grafts,
according to the current state of the art the bone marrow-
derived cells would not bear any vasculogenic capacity.
Reviewer II: What motivated your decision to use fibrin
for wrapping the SVF cells around the scaffolds as opposed
to seeding cells directly onto the scaffold surface (e.g.,
pre-coated with an adhesion molecule such as fibronectin)?
MTT staining indicated a heterogeneous application of the
cells as aggregates along the scaffold periphery. Do you
think this could have reduced cell retention at the ectopic
site, and if so, how might the application technique be
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altered in order to improve homogeneity in cell
distribution?
Authors:The use of fibrin for wrapping SVF cells around
the scaffolds was based on the method proposed by Bensaid
and collegues, and was introduced to achieve an instant
seeding of cells. Indeed, both a perfusion-based seeding
method developed and used in our group (Wendt et al.,
2003; Scherberich et al., 2007) and a more typical static
loading of a cell suspension require at least a couple of
hours before cells are stably adhered to the scaffolds. We
are aware of the possible limitations of our method for
maintenance of the cells into the construct at the ectopic
site. For this reason, in more recent experiments performed
for a related project (not yet published), we mixed the
polymerizing fibrin gel with granulate materials, as
opposed to wrapping it around monolithic, cylindrical
foams. The homogeneity of the seeding was improved,
but this still did not result in generation of bone tissue by
the seeded cells.
Reviewer II:  In the discussion, you state that future studies
will evaluate modifications to the intraoperative protocol
that incorporate growth factors, instructive biomaterials,
or perhaps both to enhance bone repair by SVF cells. Given
that these cells are clonogenic yet non-expanded, might a
two-pronged stimulation – first to initiate a period of cell
expansion, then to direct osteogenic differentiation – be
advantageous over introduction of a single stimulus?
Authors: It would indeed be highly relevant to induce a
sequential stimulation which would first promote cell
proliferation, to reach the important target of a higher cell
density, and to later drive cell osteogenic commitment.
Strategies to release different factors at different kinetics,
for instance based on incorporation into polymeric
materials and microspheres, have already been  achieved
by different groups. However, the practical implementation
into a clinical setting of such strategies may not be
straightforward in terms of regulatory issues and costs,
and could thus represent a main limit of what is envisioned
to be a practical, simple solution to generate osteogenic
grafts in the setting of the operating room at low additional
cost.
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